Actively Recruiting
Danish Angle Closure Prevention Trial
Led by University of Aarhus · Updated on 2023-11-13
242
Participants Needed
5
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine whether primary angle closure suspects (PACS) in a Caucasian population benefit from prophylactic laser iridotomy.
CONDITIONS
Official Title
Danish Angle Closure Prevention Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Primary angle closure suspect with at least 180 degrees of irido-trabecular contact on darkroom gonioscopy
- Intraocular pressure less than 21 mmHg
- No peripheral anterior synechiae
- No glaucomatous optic neuropathy
- Best-corrected visual acuity better than 0.8 in both eyes
- Caucasian ethnicity
- Age between 40 and 80 years
You will not qualify if you...
- Previous cataract surgery (pseudophakia)
- Previous iridotomy
- Clinically significant cataract requiring surgery
- Diagnosis of glaucoma
- Uveitis
- Unstable retinal conditions
- Eye cancers
- Presence of pseudoexfoliation syndrome (PEX)
- Presence of pigment dispersion syndrome (PDS)
- Current systemic or ocular corticosteroid treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Aalborg University Hospital
Aalborg, Denmark, 9000
Actively Recruiting
2
Aarhus University Hospital
Aarhus, Denmark, 8240
Actively Recruiting
3
Rigshospitalet Glostrup
Glostrup Municipality, Denmark, 2600
Actively Recruiting
4
Odense University Hospital
Odense, Denmark, 5000
Not Yet Recruiting
5
Sygehus Lillebælt
Vejle, Denmark, 7100
Actively Recruiting
Research Team
N
Niklas Telinius, PhD, DMSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here